-
Views
-
Cite
Cite
Steven M. Opal, James C. Keith, Jhung Jhung, John E. Palardy, Nicolas Parejo, Erik Marchese, Vasu Maganti, Orally Administered Recombinant Human Interleukin-11 Is Protective in Experimental Neutropenic Sepsis, The Journal of Infectious Diseases, Volume 187, Issue 1, 1 January 2003, Pages 70–76, https://doi.org/10.1086/345864
- Share Icon Share
Abstract
Recombinant human interleukin (IL)–11 is a multifunctional cytokine with hematopoietic, immunomodulatory, and epithelial cell protective activities. IL-11α receptors are expressed on the luminal surface of intestinal epithelial cells. It was hypothesized that orally administered IL-11 would prevent mucosal damage and protect against microbial invasion in a neutropenic rat model of gram-negative sepsis. IL-11 was administered daily by enteric, coated multiparticle pellets over the course of chemotherapy-induced neutropenia. Compared with the placebo group, IL-11–treated rats retained mucosal mass and had prolonged survival time, reduced pathologic changes, and reduced systemic levels of bacterial endotoxin and concentrations of Pseudomonas aeruginosa in target tissues. Enterocyte messenger RNA levels for tumor necrosis factor–α and interferon-γ revealed that oral IL-11 reduced but did not prevent increased expression of these cytokine genes. These results indicate that orally administered IL-11 may preserve epithelial cell integrity in the presence of cytoreductive chemotherapy. This may represent a new treatment strategy for the prevention of infection in neutropenic hosts
- cytokine
- pseudomonas aeruginosa
- sepsis
- endotoxins
- tumor necrosis factors
- chemotherapy regimen
- neutropenia
- neutropenia, drug-induced
- enterocytes
- interferons
- interleukin-11
- interleukins
- intestines
- rna, messenger
- mucous membrane
- phenobarbital
- rats
- epithelial cells
- human leukocyte interferon
- gram-negative septicemia
- personal integrity